-

Rapid Medical™ Gains Approval in China for the World’s Only Adjustable Thrombectomy Device

TIGERTRIEVER™ is designed to accelerate clot integration and reduce vessel damage in ischemic stroke

YOKNEAM, Israel & MIAMI--(BUSINESS WIRE)--Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval for its TIGERTRIEVER revascularization device. With this milestone of National Medical Product Administration (NMPA) approval, TIGERTRIEVER becomes the first device to offer patient-specific solutions for removing blood clots from the brain to advance the treatment of ischemic stroke.

“This new approval for TIGERTRIEVER propels treatment for ischemic stroke patients in China,” says Ronen Eckhouse, co-founder and CEO at Rapid Medical. “We are fortunate to have an excellent partner with MicroPort Scientific Corporation, who understand the need to expand neurointerventional capabilities and individualized stroke care for these patients.”

TIGERTRIEVER technology, fueled by advancements in aerospace engineering, enables precise control during mechanical thrombectomy. Its unique operation changes these procedures from a passive to an active approach that accelerates clot capture and potentially reduces the risk of vascular injury during removal. Comparable, leading stent retrievers are self-expanding and static, which can lead to suboptimal clot removal and minimal vessel protection.

Published clinical studies demonstrate superiority to conventional stent retrievers. The results of the TIGER multicenter trial presented 3 statistically significant improvements– in restoring blood flow to the brain, good clinical outcomes, and reducing emboli to new territory–compared to an average from six pivotal stent retriever trials.1 Additionally, the TIGER trial showed fast procedure times, on par with aspiration alone2, driven by a very high rate of first-pass success.

“The successful launch of TIGERTRIEVER in China represents another stroke intervention innovation that can be applied in the real world, introducing the concept of tailored thrombectomy using an adjustable stent retriever that allows physicians to navigate procedures and unexpected circumstances with added control,” said Zhiyong Xie, President at MicroPort NeuroTech. “TIGERTRIEVER provides Chinese physicians with a new choice of neurological intervention medical devices that will benefit more patients.”

About Rapid Medical

Rapid Medical holds an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation headquartered in China. Rapid Medical pioneers advanced interventional devices to treat neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER XL is also CE marked. More information is available at www.rapid-medical.com

______________________
1 Gupta, Rishi et al. “New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.” Stroke vol. 52,5 (2021): 1534-1544. doi:10.1161/STROKEAHA.121.034436
2 Turk, Aquilla S 3rd et al. “Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial.” Lancet (London, England)vol. 393,10175 (2019): 998-1008. doi:10.1016/S0140-6736(19)30297-1

Contacts

Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com

Rapid Medical


Release Summary
Rapid Medical gains approval in China for TIGERTRIEVER, the only thrombectomy device that adjusts to each patient to advance ischemic stroke treatment

Contacts

Ronen Eckhouse
+972-72-2503331
ronen@rapid-medical.com

Social Media Profiles
More News From Rapid Medical

Rapid Medical™ Announces Enrollment in the First-Ever Study on the Cognitive Benefits of Thrombectomy for Ischemic Stroke Patients-Enabled by Advancements in Endovascular Devices

SOUTHLAKE, Texas--(BUSINESS WIRE)--Rapid Medical™ enrolls in the first study of the cognitive benefits of thrombectomy for ischemic stroke-enabled by TIGERTRIEVER’s active technology...

Rapid Medical™ Reports No Safety Concerns for Medium Vessel Occlusions in the Interim Safety Analysis of the DISTALS Study with TIGERTRIEVER™13

YOKNEAM, Israel & SOUTHLAKE, Texas & MARSEILLE, France--(BUSINESS WIRE)--Interim safety analysis of Rapid Medical's TIGERTRIEVER 13 device in the DISTALS study for medium vessel strokes concludes no safety concerns....

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

YOKNEAM, Israel & COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Rapid Medical completes the first cases in the USA with the high-performance, deflectable access solution DRIVEWIRE 24 following FDA clearance....
Back to Newsroom